Advaxis (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Advaxis (NASDAQ:ADXSGet Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the stock.

NASDAQ:ADXS opened at $0.07 on Tuesday. Advaxis has a 1 year low of $0.06 and a 1 year high of $0.71.

About Advaxis (Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Further Reading

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.